{"entity":{"id":"nct07257653","kind":"trial","name":"The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresect","aka":["concept"],"tldr":"A phase 2 trial in colorectal cancer, run by Zhejiang University, now recruiting.","summary":"The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer is a phase 2, randomised interventional study registered as NCT07257653 by Zhejiang University, with a registry enrolment figure of 70 participants, started 2025-10-21 and due to reach its primary completion in 2026-12-31. Interventions recorded: Cetuximab β；Fruquintinib；; Cetuximab β；Fruquintinib；anti-PD1 antibody；; Cetuximab β；Fruquintinib；anti-PD1/CTLA4 antibody. Conditions listed: Colorectal Neoplasms; RAS; BRAF; Cetuximabβ; Fruquintinib. Primary outcome: PFS. Colorectal eligibility wording from the registry: \"For patients aged 80-85, comprehensive functional assessments must be completed, and they may be enrolled if the investigator deems them tolerable, with an expected survival of over 3 months; 3) Histopathologically and/or cytologically confirmed, unresectable metastatic colorectal adenocarcinoma con\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07257653","url":"https://clinicaltrials.gov/study/NCT07257653"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07257653","phase":"2","setting":"The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer","sponsor":"Zhejiang University","enrolled":70,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07257653/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}